DNMT1 and pachyonychia congenita: More encouragingly, phase I/II clinical trials of DNMT1 inhibitors (azacitidine, decitabine, and guadecitabine) in PC patients are currently underway, the inhibitors which exhibited potential treatment outcomes [47].